✉news HealthMedicine first seen 15 h ago, last 4 h ago, peak #2
Oral GLP-1 pill safiglipron shows promise in early type 2 diabetes trial
Original: Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.
Why now: GLP-1 drugs are a major focus of diabetes and obesity treatment, and an effective oral pill would be a significant step forward.
safiglipronNaturetype 2 diabetes
Rank over time, top of the chart is #1. 6 snapshots from 11 h ago to 4 h ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/436753